首页> 美国卫生研究院文献>Clinical Cardiology >Filterwire™ distal embolic protection device for vein graft stenting: Initial single‐center experience
【2h】

Filterwire™ distal embolic protection device for vein graft stenting: Initial single‐center experience

机译:用于静脉移植物支架的Filterwire™远端栓塞保护装置:最初的单中心经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Saphenous vein graft (SVG) intervention is associated with a significant incidence of major adverse cardiac events (MACE) related to distal vessel embolization. The FilterWire™ distal embolic protection device has recently been approved as an adjunct to SVG intervention. We report here our initial experience in a single center in 30 consecutive patients using this device in SVG stenting. Hypothesis: This study examined the outcomes and complications associated with these devices, as well as whether proficiency with the devices increased with greater experience and whether there were measurable outcome differences between devices. Methods: We retrospectively identified all patients in whom a FilterWire device was placed at our hospital between June 2001 and June 2004. Results: The device was successfully deployed in 29 of 30 patients, and all patients were stented successfully. Overall MACE rate was 6.6%, consistent with reports in larger multi‐center clinical trials. Transient decreases in flow were noted while the device was in place in six patients, but improved in five patients with device removal. Conclusions: This early experience in a single center using FilterWire embolic protection indicates that excellent clinical results can be obtained by the adoption of filter protection for SVG intervention, without evidence for a detrimental learning curve.
机译:背景:大隐静脉移植(SVG)干预与与远端血管栓塞相关的重大不良心脏事件(MACE)的发生率很高。 FilterWire™远端栓塞保护装置最近已被批准作为SVG干预的辅助手段。我们在这里报告了我们在30个连续患者中使用该设备进行SVG支架置入单个中心的初步经验。假设:这项研究检查了与这些器械相关的结局和并发症,以及随着经验的增加,器械的熟练度是否增加,以及器械之间是否存在可测量的结果差异。方法:我们回顾性分析了2001年6月至2004年6月间在我院安装了FilterWire装置的所有患者。结果:该装置已成功部署在30例患者中的29例中,所有患者均已成功植入支架。总体MACE率为6.6%,与大型多中心临床试验中的报告一致。在装置安装到位时,有六名患者注意到了短暂的血流减少,但在有装置移除的五名患者中,流量有所减少。结论:在单个中心使用FilterWire栓塞防护的早期经验表明,通过对SVG干预采用过滤器防护可以获得良好的临床效果,而无不利于学习曲线的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号